125 related articles for article (PubMed ID: 8022849)
1. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro.
Basu S; Sjöquist B; Stjernschantz J; Resul B
Prostaglandins Leukot Essent Fatty Acids; 1994 Apr; 50(4):161-8. PubMed ID: 8022849
[TBL] [Abstract][Full Text] [Related]
2. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
3. Delta13-reductase dependent metabolism of prostaglandins in the mammalian brain and eye.
Basu S; Stjernschantz J
Prostaglandins Leukot Essent Fatty Acids; 1997 Sep; 57(3):305-10. PubMed ID: 9384521
[TBL] [Abstract][Full Text] [Related]
4. Expression of NADP+-dependent 15-hydroxyprostaglandin dehydrogenase mRNA in monkey ocular tissues and characterization of its recombinant enzyme.
Fujimori K; Okada T; Urade Y
J Biochem; 2002 Mar; 131(3):383-9. PubMed ID: 11872167
[TBL] [Abstract][Full Text] [Related]
5. Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro.
Madhu C; Rix P; Nguyen T; Chien DS; Woodward DF; Tang-Liu DD
J Ocul Pharmacol Ther; 1998 Oct; 14(5):389-99. PubMed ID: 9811228
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment.
Hotehama Y; Mishima HK
Jpn J Ophthalmol; 1993; 37(3):259-69. PubMed ID: 8295363
[TBL] [Abstract][Full Text] [Related]
7. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
Ziai N; Dolan JW; Kacere RD; Brubaker RF
Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
Sjöquist B; Johansson A; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):240-9. PubMed ID: 10219468
[TBL] [Abstract][Full Text] [Related]
9. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester.
Bito LZ; Baroody RA
Exp Eye Res; 1987 Feb; 44(2):217-26. PubMed ID: 3472899
[TBL] [Abstract][Full Text] [Related]
10. In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
Woodward DF; Chan MF; Cheng-Bennett A; Wheeler LA; Chen G; Burke JA; Kharlamb A; Lai RK; Shan T
Exp Eye Res; 1996 Oct; 63(4):411-23. PubMed ID: 8944548
[TBL] [Abstract][Full Text] [Related]
11. Cloning of guinea pig cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase complementary deoxyribonucleic acids: steroid-modulated gene expression correlates to prostaglandin F2 alpha secretion in cultured endometrial cells.
Bracken KE; Elger W; Jantke I; Nanninga A; Gellersen B
Endocrinology; 1997 Jan; 138(1):237-47. PubMed ID: 8977409
[TBL] [Abstract][Full Text] [Related]
12. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
Toris CB; Camras CB; Yablonski ME
Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
[TBL] [Abstract][Full Text] [Related]
13. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
Bito LZ; Stjernschantz J; Resul B; Miranda OC; Basu S
J Lipid Mediat; 1993; 6(1-3):535-43. PubMed ID: 8358014
[TBL] [Abstract][Full Text] [Related]
14. Lack of prostaglandin F2 alpha metabolism by human ocular tissues.
Cheng-Bennett A; Poyer J; Weinkam RJ; Woodward DF
Invest Ophthalmol Vis Sci; 1990 Jul; 31(7):1389-93. PubMed ID: 2365570
[TBL] [Abstract][Full Text] [Related]
15. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia.
Astin M; Stjernschantz J; Selén G
Exp Eye Res; 1994 Oct; 59(4):401-7. PubMed ID: 7532135
[TBL] [Abstract][Full Text] [Related]
16. Development of a radioimmunoassay for latanoprost and its application in a long-term study in monkeys.
Basu S; Sjöquist B
Prostaglandins Leukot Essent Fatty Acids; 1996 Dec; 55(6):427-32. PubMed ID: 9014221
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
Sjöquist B; Tajallaei S; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466
[TBL] [Abstract][Full Text] [Related]
18. Studies on a novel series of acyl ester prodrugs of prostaglandin F2 alpha.
Cheng-Bennett A; Chan MF; Chen G; Gac T; Garst ME; Gluchowski C; Kaplan LJ; Protzman CE; Roof MB; Sachs G
Br J Ophthalmol; 1994 Jul; 78(7):560-7. PubMed ID: 7918269
[TBL] [Abstract][Full Text] [Related]
19. Initial clinical studies with prostaglandins and their analogues.
Camras CB; Alm A
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S61-8. PubMed ID: 9154278
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids.
Resul B; Stjernschantz J; Selén G; Bito L
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S47-52. PubMed ID: 9154276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
